Genmab — Oktober 2016
-
@henrik48. COPENHAGEN, Denmark--Back in June, Merck announced its immuno-oncology star Keytruda had pulled off a win in first-line non-small cell lung cancer, beating chemo at staving off disease progression and extending patients’ lives.
-
Keytruda (pembrolizumab) slashed the risk of disease progression or death by 50% and the risk of death by 40% among patients expressing PD-L1 levels of 50% or greater in the Keynote-024 trial, the drugmaker said. Median progression-free survival for patients on Keytruda came in at 10.3 months, versus 6 months for those on chemo.
-
Det var her BMYs Opdivo fejlede for nogle uger siden
-
Keytruda er også en konkurrent til Darzalex. Idet der formodentlig snart indledes studier hvor Darzalex kombineres med Tecentriq fra Roche
-
Det er i hvert fald det der spekuleres kan være første kombi for Darzalex i solide tumorer. Altså lungekræft...
-
Solsen - dvs du forventer et Janssen / Merck samarbejde omkring Darzalex / Keytruda i forskellige indikationer?
-
Solsen - jeg mente ikke Keytruda var en konkurrent i MM, men i lungekræft. Men de kan kombineres med succes er det jo nærmere en partner
-
men hvis de....
-
@bikube. Verden forandrer sig enormt hurtigt. Indtil for 3 måneder siden anbefalede stort set alle analytikere BMY pga Opdivos fantastiske evner. Et mislykket første linie studie i lungekræft, og de er bare fuldstændig yt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind